1.905
Tango Therapeutics Inc stock is traded at $1.905, with a volume of 1.47M.
It is up +2.14% in the last 24 hours and up +29.59% over the past month.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
See More
Previous Close:
$1.865
Open:
$1.83
24h Volume:
1.47M
Relative Volume:
1.08
Market Cap:
$206.48M
Revenue:
$42.51M
Net Income/Loss:
$-116.49M
P/E Ratio:
-1.7009
EPS:
-1.12
Net Cash Flow:
$-120.82M
1W Performance:
+27.00%
1M Performance:
+29.59%
6M Performance:
-51.40%
1Y Performance:
-73.13%
Tango Therapeutics Inc Stock (TNGX) Company Profile
Name
Tango Therapeutics Inc
Sector
Industry
Phone
(857) 320-4900
Address
201 BROOKLINE AVENUE, BOSTON
Compare TNGX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TNGX
Tango Therapeutics Inc
|
1.905 | 164.76M | 42.51M | -116.49M | -120.82M | -1.12 |
![]()
ONC
Beigene Ltd Adr
|
241.93 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
434.78 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.31 | 42.47M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
588.22 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
75.03 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-17-24 | Initiated | Jefferies | Buy |
Apr-04-24 | Initiated | Cantor Fitzgerald | Overweight |
Feb-12-24 | Initiated | Piper Sandler | Overweight |
Dec-08-23 | Initiated | B. Riley Securities | Buy |
Oct-20-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
Sep-20-21 | Initiated | SVB Leerink | Outperform |
View All
Tango Therapeutics Inc Stock (TNGX) Latest News
Tango Therapeutics doses first subject in trial for MTAP-deleted tumours - Yahoo Finance
Tango Therapeutics starts trial for brain cancer drug By Investing.com - Investing.com South Africa
Tango Therapeutics Doses First Patient for Phase 1/2 Trial to Treat Brain Cancer - marketscreener.com
TNGX Initiates Phase 1/2 Trial for MTAP-Deleted Tumors | TNGX Stock News - GuruFocus
Tango Therapeutics Announces First Patient Dosed in TNG456 - GlobeNewswire
Tango Launches Phase 1/2 Trial for Brain Cancer Drug: New Hope for Deadly Glioblastoma Treatment - Stock Titan
Cantor Fitzgerald Issues Positive Estimate for TNGX Earnings - Defense World
Leerink Partnrs Analysts Boost Earnings Estimates for TNGX - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance
US$10.43: That's What Analysts Think Tango Therapeutics, Inc. (NASDAQ:TNGX) Is Worth After Its Latest Results - simplywall.st
Dimensional Fund Advisors LP Purchases 302,087 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates - MSN
Tango Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Tango Therapeutics, Inc. (NASDAQ:TNGX) Holdings Boosted by Wells Fargo & Company MN - Defense World
Tango Therapeutics Extends Cash Runway Amid Clinical Progress - TipRanks
Tango Therapeutics (TNGX) Plans $400 Million Mixed Securities Sh - GuruFocus
Tango Therapeutics Files For Mixed Shelf Of Up To $400 Million - marketscreener.com
Tango Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Tango Therapeutics Inc (TNGX) Q1 2025 Earnings: EPS of -$0.36 Mi - GuruFocus
TNGX Reports Q1 Revenue Miss, Advances Cancer Treatments | TNGX Stock News - GuruFocus
Tango Therapeutics, Inc. SEC 10-Q Report - TradingView
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewswire
Barclays PLC Has $307,000 Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics (TNGX) to Release Earnings on Monday - Defense World
Insights into Tango Therapeutics's Upcoming Earnings - Nasdaq
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of “Buy” by Analysts - Defense World
21,500 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Acquired by Renaissance Technologies LLC - Defense World
JPMorgan Chase & Co. Has $97,000 Stock Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study - Barchart.com
There is no way Tango Therapeutics Inc (TNGX) can keep these numbers up - Sete News
Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - GlobeNewswire
Is Tango Therapeutics Inc (TNGX) worth investing in despite its undervalued state? - uspostnews.com
Tango Therapeutics Inc (TNGX) Stock: A Year of Highs and Lows - investchronicle.com
Insider’s View: Deciphering Tango Therapeutics Inc (TNGX)’s Financial Health Through Ratios - DWinneX
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Acquired by Geode Capital Management LLC - Defense World
Now Is The Time To Build A Position In Tango Therapeutics Inc (NASDAQ:TNGX) - Marketing Sentinel
Press Release Distribution & PR Platform - ACCESS Newswire
Gaining Ground: Tango Therapeutics Inc (TNGX) Closes Lower at 2.35, Down -0.42 - DWinneX
What is the investor’s view on Tango Therapeutics Inc (TNGX)? - uspostnews.com
Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Acquired by Franklin Resources Inc. - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $12.33 Average PT from Analysts - Defense World
Equities Analysts Offer Predictions for TNGX Q1 Earnings - Defense World
Tango Bypasses IPO Route With SPAC Merger - insights.citeline.com
What is HC Wainwright’s Estimate for TNGX Q1 Earnings? - Defense World
Tango Therapeutics’ (TNGX) Buy Rating Reaffirmed at HC Wainwright - Defense World
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Tango Therapeutics stock holds Buy rating, $13 target from H.C. Wainwright - Investing.com Canada
Tango Therapeutics stock holds Buy rating, $13 target from H.C. Wainwright By Investing.com - Investing.com South Africa
Little Excitement Around Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Revenues As Shares Take 28% Pounding - simplywall.st
Tango Therapeutics Inc Stock (TNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):